Crucell Holland BV
Leiden
About Crucell Holland BV
Crucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 5,001 – 10,000
- Total funding: $443.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2009)
- Ticker: nasdaq:CRXL
- Website: crucell.com
- Phone: 31 71 519 9100
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/crucell-holland-bv-1015876 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.